• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低分子量蛋白质作为肾脏药物靶向载体。药物 - 蛋白质缀合物和药物 - 间隔基衍生物的制备及其在肾皮质匀浆和溶酶体裂解物中的分解代谢。

Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.

作者信息

Franssen E J, Koiter J, Kuipers C A, Bruins A P, Moolenaar F, de Zeeuw D, Kruizinga W H, Kellogg R M, Meijer D K

机构信息

Department of Pharmacology and Pharmacotherapy, University Center for Pharmacy, Groningen, The Netherlands.

出版信息

J Med Chem. 1992 Apr 3;35(7):1246-59. doi: 10.1021/jm00085a012.

DOI:10.1021/jm00085a012
PMID:1560438
Abstract

Low molecular weight proteins (LMWPs) are known to be reabsorbed and catabolized primarily by the proximal tubular cells of the kidneys. As such, LMWPs might serve as drug carriers that release drugs site-specifically in the kidney. We tested this concept in vitro by coupling different drugs to the LMWP lysozyme both directly (amide bond) and via different spacers: oligopeptides (amide bond), (poly-)alpha-hydroxy acids (ester bond), and a pH sensitive cis-aconityl spacer (amide bond). The capability of the kidney to release the parent drug from such drug-spacer derivatives and drug-LMWP conjugates by enzymatic or chemical hydrolysis of the bond was tested by incubation experiments in renal cortex homogenates and lysosomal lysates. Directly coupled conjugates of terminal carboxyl group containing drugs and lysozyme were catabolized to single amino acids, but did not result in release of the parent drug. The amide bond between the drug and the final amino acid (lysine) appeared to be stable in the incubation milieu. Different oligopeptide spacers coupled to the drugs showed similar results: the oligopeptide itself was cleaved but the amide bond between the drug and different single amino acids remained untouched. Only amide bonds of derivatives of carboxylic drugs with peptide structures themselves were cleaved. Some of the directly coupled conjugates of terminal amino drugs and oligopeptides showed clear release of the parent drug whereas others were stable. Terminal amino drugs were rapidly released from an acid-sensitive cis-aconityl spacer. Terminal carboxyl group containing drugs were enzymatically released from their glycolic and lactic ester spacers at different rates. These kinds of drugs were also released as parent drug from LMWP conjugates with ester spacers like L-lactic acid. Increasing spacer length by intercalating a tetra(L-lactic acid) molecular between the drug and the protein further increased the extent and rate of drug release, indicating increased accessibility of the bond to the enzymes. Terminal amino group containing drugs were rapidly generated as parent drug from LMWP conjugates using an acid-sensitive spacer. In addition the conjugates were found to be adequately stable in plasma, considering their rapid clearance from the bloodstream. It is concluded that LMWPs may indeed be of use as carriers for specific renal delivery of drugs, since renal cortex homogenates and lysosomal lysates are able to catabolize the protein and generate the parent drug from drug-LMWP conjugates bearing suitable spacers. The option of enzymatic release is limited by the narrow specificity of the lysosomal enzymes.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

已知低分子量蛋白质(LMWPs)主要由肾脏近端肾小管细胞重吸收和分解代谢。因此,LMWPs可能用作药物载体,在肾脏中实现药物的位点特异性释放。我们在体外通过将不同药物直接(酰胺键)以及经由不同间隔基与LMWP溶菌酶偶联来测试这一概念:寡肽(酰胺键)、(聚)α-羟基酸(酯键)以及一种pH敏感的顺乌头酰间隔基(酰胺键)。通过在肾皮质匀浆和溶酶体裂解物中进行孵育实验,测试肾脏通过对键进行酶促或化学水解从这类药物-间隔基衍生物和药物-LMWP缀合物中释放母体药物的能力。含末端羧基药物与溶菌酶的直接偶联缀合物被分解代谢为单个氨基酸,但未导致母体药物的释放。药物与最终氨基酸(赖氨酸)之间的酰胺键在孵育环境中似乎是稳定的。与药物偶联的不同寡肽间隔基显示出相似的结果:寡肽本身被裂解,但药物与不同单个氨基酸之间的酰胺键未受影响。只有具有肽结构的羧酸药物衍生物的酰胺键被裂解。一些含末端氨基药物与寡肽的直接偶联缀合物显示出母体药物的明显释放,而其他的则是稳定的。末端氨基药物从酸敏感的顺乌头酰间隔基快速释放。含末端羧基的药物以不同速率从其乙醇酸和乳酸酯间隔基中酶促释放。这类药物也作为母体药物从与L-乳酸等酯间隔基的LMWP缀合物中释放。通过在药物与蛋白质之间插入一个四(L-乳酸)分子来增加间隔基长度,进一步提高了药物释放的程度和速率,表明键对酶的可及性增加。使用酸敏感间隔基时,含末端氨基的药物从LMWP缀合物中快速生成母体药物。此外,考虑到它们从血液中的快速清除,发现这些缀合物在血浆中具有足够的稳定性。得出的结论是,LMWPs确实可能用作药物特异性肾脏递送的载体,因为肾皮质匀浆和溶酶体裂解物能够分解代谢蛋白质,并从带有合适间隔基的药物-LMWP缀合物中生成母体药物。酶促释放的选择受到溶酶体酶狭窄特异性的限制。(摘要截短为400字)

相似文献

1
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.低分子量蛋白质作为肾脏药物靶向载体。药物 - 蛋白质缀合物和药物 - 间隔基衍生物的制备及其在肾皮质匀浆和溶酶体裂解物中的分解代谢。
J Med Chem. 1992 Apr 3;35(7):1246-59. doi: 10.1021/jm00085a012.
2
Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid.
Pharm Res. 1993 Jul;10(7):963-9. doi: 10.1023/a:1018946219057.
3
Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme.
Pharm Res. 1991 Oct;8(10):1223-30. doi: 10.1023/a:1015835325321.
4
Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers.通过寡肽间隔基连接的甲氨蝶呤载体缀合物的设计、合成及体外测试。
Anticancer Drug Des. 1995 Jan;10(1):1-9.
5
Synthesis of low-molecular weight protein (LMWP) lysozyme-curcumin conjugates for kidney drug targeting.合成低分子量蛋白(LMWP)溶菌酶-姜黄素缀合物用于肾脏药物靶向。
J Biomater Sci Polym Ed. 2013;24(11):1360-7. doi: 10.1080/09205063.2012.759506. Epub 2013 Jan 9.
6
A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.柔红霉素与蛋白质之间的共价连接,这种连接在血清中稳定且可被溶酶体水解酶逆转,这是溶酶体靶向药物 - 载体缀合物所必需的:体外和体内研究。
Proc Natl Acad Sci U S A. 1982 Jan;79(2):626-9. doi: 10.1073/pnas.79.2.626.
7
Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo.药物靶向肾脏:萘普生-溶菌酶缀合物在体内的肾脏递送与降解
Kidney Int. 1997 Dec;52(6):1693-9. doi: 10.1038/ki.1997.504.
8
Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.阿霉素通过酰胺键和腙键结合的聚合物缀合物:载体结构对治疗实体瘤协同作用的影响。
Eur J Pharm Sci. 2014 Jul 16;58:1-12. doi: 10.1016/j.ejps.2014.02.016. Epub 2014 Mar 13.
9
Effect of low molecular weight proteins and dextran on renal cathepsin B and L activity.低分子量蛋白质和右旋糖酐对肾脏组织蛋白酶B和L活性的影响。
Kidney Int. 1990 Mar;37(3):918-26. doi: 10.1038/ki.1990.66.
10
Lysosomal degradability of poly(alpha-amino acids).聚(α-氨基酸)的溶酶体降解性
J Biomed Mater Res. 1997 Mar 5;34(3):381-92. doi: 10.1002/(sici)1097-4636(19970305)34:3<381::aid-jbm13>3.0.co;2-j.

引用本文的文献

1
Kidney-targeted drug delivery systems.肾脏靶向给药系统。
Acta Pharm Sin B. 2014 Feb;4(1):37-42. doi: 10.1016/j.apsb.2013.12.005. Epub 2014 Jan 23.
2
Prodrugs for amines.胺类前药。
Molecules. 2008 Mar 3;13(3):519-47. doi: 10.3390/molecules13030519.
3
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.一项针对实体瘤成年患者的I期研究,采用MAG-喜树碱静脉给药,每周一次,共3周,每4周为一个周期。
Br J Cancer. 2004 Jun 14;90(12):2261-7. doi: 10.1038/sj.bjc.6601811.
4
Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic acid as novel naproxen prodrugs for dermal drug delivery.2-(6-甲氧基-2-萘基)丙酸的氨酰氧基烷基酯作为用于皮肤给药的新型萘普生前药的合成及体外评价
Pharm Res. 1999 Aug;16(8):1172-8. doi: 10.1023/a:1018981010047.
5
Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid.
Pharm Res. 1993 Jul;10(7):963-9. doi: 10.1023/a:1018946219057.
6
Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme.
Pharm Res. 1991 Oct;8(10):1223-30. doi: 10.1023/a:1015835325321.